Company intelligence / Profile preview

PathoGenesis

Seattle, Washington, United States

Ownership: Private
Employees: ~275
Development stage: Other

Overview

PathoGenesis developed TOBI (tobramycin) inhalation solution, an antibiotic approved for managing chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. The product was successfully commercialized before the company's acquisition, with annual sales exceeding $60 million in 1999. The company also had a preclinical program in tuberculosis.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small moleculeAntibiotic
Industry: Biotech

Beyond the preview

Go deeper on PathoGenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PathoGenesis.

Explore the full profile